LEADER 00705nam0-22002771i-450- 001 990007137330403321 005 20021010 035 $a000713733 035 $aFED01000713733 035 $a(Aleph)000713733FED01 035 $a000713733 100 $a20021010d--------km-y0itay50------ba 101 0 $aita 200 1 $a<>Era atomica$fRoberto Maiocchi. 210 $aFirenze$cGiunti$d1993. 215 $a157 p.$d20 cm 225 1 $aCollana XX secolo 700 1$aMaiocchi,$bRoberto$052968 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990007137330403321 952 $aXVI C 13$b1393$fDDCIC 959 $aDDCIC 996 $aEra atomica$9187639 997 $aUNINA DB $aGEN01 LEADER 05246nam 2200661Ia 450 001 9910830408003321 005 20230607214150.0 010 $a1-280-27006-3 010 $a9786610270064 010 $a0-470-35829-7 010 $a0-470-85458-8 010 $a0-470-85459-6 035 $a(CKB)111087027141088 035 $a(EBL)158120 035 $a(OCoLC)232330672 035 $a(SSID)ssj0000133011 035 $a(PQKBManifestationID)11136347 035 $a(PQKBTitleCode)TC0000133011 035 $a(PQKBWorkID)10044944 035 $a(PQKB)10290408 035 $a(MiAaPQ)EBC158120 035 $a(EXLCZ)99111087027141088 100 $a20020730d2002 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 10$aCross-over trials in clinical research$b[electronic resource] /$fStephen Senn 205 $a2nd ed. 210 $aChichester ;$aHoboken, NJ $cJ. Wiley$dc2002 215 $a1 online resource (363 p.) 225 1 $aStatistics in practice 300 $aDescription based upon print version of record. 311 $a0-471-49653-7 320 $aIncludes bibliographical references (p. 323-334) and indexes. 327 $aCross-over Trials in Clinical Research; Contents; Preface to the second edition; Preface to the first edition; 1 Introduction; 1.1 The purpose of this chapter; 1.2 An example; 1.3 Why are cross-over trials performed?; 1.4 What are the disadvantages of cross-over trials?; 1.5 Where are cross-over trials useful?; 1.6 What attitude to cross-over trials will be adopted in this book?; 1.7 Carry-over; 1.8 What may be done about carry-over?; 1.9 Other attitudes to be adopted; 1.10 Where else can one find out about cross-over trials? 327 $a2 Some basic considerations concerning estimation in clinical trials*2.1 The purpose of this chapter; 2.2 Assumed background knowledge; 2.3 Control in clinical trials; 2.4 Two purposes of estimation; 2.5 Some features of estimation; 2.6 Practical consequences for cross-over trials; 3 The AB/BA design with Normal data; 3.1 An example; 3.2 A simple analysis ignoring the effect of period; 3.3 Student's approach*; 3.4 Assumptions in the matched-pairs t approach; 3.5 Adjusting for a period effect: two-sample t approach; 3.6 Adjusting for a period effect: the Hills-Armitage approach 327 $a3.7 Examining period effects3.8 Testing for carry-over and/or treatment by period interaction*; 3.9 A model for the AB/BA cross-over*; 3.10 Carry-over or treatment by period interaction?*; 3.11 Confidence intervals for carry-over*; 3.12 Are unbiased estimators of the treatment effect available?*; 3.13 Can we adjust for carry-over?*; 3.14 The two-stage analysis*; 3.15 Correcting the two-stage procedure*; 3.16 Use of baseline measurements; 3.17 A Bayesian approach; 3.18 Computer analysis; 3.19 Further reading; 3.20 Recommendations; Appendix 3.1 Analysis with GenStatŪ 327 $aAppendix 3.2 Analysis with S-PlusŪ4 Other outcomes and the AB/BA design; 4.1 Introduction; 4.2 Transformations; 4.3 Non-parametric methods; 4.4 Binary outcomes; 4.5 Ordered categorical data; 4.6 Frequency data; 4.7 'Survival' data*; 4.8 Final remarks; Appendix 4.1 Analysis with GenStatŪ; Appendix 4.2 Analysis with S-PlusŪ; 5 Normal data from designs with three or more treatments; 5.1 Why do we have designs with three or more treatments?; 5.2 Sequences for trials with three or more treatments; 5.3 Analyses ignoring the effect of period; 5.4 Allowing for period effects 327 $a5.5 Other miscellaneous issues5.6 Recommendations; Appendix 5.1 Analysis with GenStatŪ; Appendix 5.2 Analysis with S-PlusŪ; 6 Other outcomes from designs with three or more treatments; 6.1 Introduction; 6.2 Analyses which take no account of period effects; 6.3 Non-parametric analyses adjusting for period effects; 6.4 Hodges-Lehmann type estimators*; 6.5 A stratified period adjusted sign test; 6.6 Binary data; 6.7 Other analyses; Appendix 6.1 Analysis with GenStatŪ; Appendix 6.2 Analysis with S-PlusŪ; 7 Some special designs; 7.1 The scope of this chapter; 7.2 Factorial designs 327 $a7.3 Incomplete block designs 330 $aCross-over trials are an important class of design used in the pharmaceutical industry and medical research, and their use continues to grow. Cross-over Trials in Clinical Research, Second Edition has been fully updated to include the latest methodology used in the design and analysis of cross-over trials. It includes more background material, greater coverage of important statistical techniques, including Bayesian methods, and discussion of analysis using a number of statistical software packages.* Comprehensive coverage of the design and analysis of cross-over trials.* Each techn 410 0$aStatistics in practice. 606 $aCrossover trials 606 $aClinical trials 615 0$aCrossover trials. 615 0$aClinical trials. 676 $a615.19 676 $a615.5/07/2 700 $aSenn$b Stephen$0116896 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910830408003321 996 $aCross-over trials in clinical research$93986223 997 $aUNINA